New Approved Drug For Skin Cancer
According to the researchers from the UCLA cancer center, a new drug has been approved for the patients suffering metastatic melanoma. This particular kind of drug can be used for treating bad kind of skin cancer.
The data was collected from the patients for one year. Melanoma is a serious problem and patient suffering from melanoma hardly survives for about nine months. Patients taking the Zelboraf drug and which mainly blocks the BRAF protein can survive for 15.9 months. Zelboraf has really changed history of this particular problem. Good numbers of patients are getting perfect results by the intake of this particular drug. They are also living longer as compared to the patients not taking this drug. There is a very good impact of the Zelboraf on patients and this has changed the method of treating metastatic melanoma.
Patients suffering from metastatic melanoma have this BRAF mutation and can take Zelboraf twice a day. It was seen that among 53% patients had their tumors shrink by 30%. Other 30% patients were having tumor of very less dimension. The study also revealed that just 14% patient could not respond to Zelboraf.
Zelboraf is a kind of revolution that is done for treating metastatic melanoma. This particular kind of process worked better than chemotherapy. Patients taking Zelboraf are living for a longer period of time. Zelboraf is approved and the results are unimaginable. The rate of using this particular drug is increasing at a very good rate.
- Drug Used In Treating Children Infected With HIV
- Diabetes Drug To Reduce Risk Of Cancer
- A Small Step Forward In Cancer Treatment
- ApoPharma’s Deferiprone For Iron Overload Approved By The FDA
- What Exactly Are Plant-Drug Interactions?
- New Cancer Treatment
- The Success Of Biogen Idec, Inc (Massachusetts) (BIIB)’s Oral Multiple Sclerosis Drug
- Stopping Skin Cancer Dead On Its Tracks
- Lower Antioxidant Levels Poses Higher Skin Cancer Rate In Males